Key Details
Price
$122.55Last Dividend
$0.46Annual ROE
8.03%Beta
1.31Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
July 02, 2010Next split:
N/ARecent split:
Nov 02, 2022Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, reinforcing my confidence in the company's performance. This analysis references Q3 2024 financial results press release, earnings conference call, presentation, 10-Q, and the latest 10-K.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - Chief Executive Officer Karen Reeves - Senior Vice President of Investments and Head of Clinical Strategy Tavo Espinoza - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Douglas Miehm - RBC Capital Markets Joseph Pantginis - Wainwright Trevor Allred - Oppenheimer John Vandermosten - Zach Small Capital Research Operator Good morning. My name is Aaron, and I will be your conference operator for today.
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as MSD outside the United States and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE™, previously known as V116, a 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population. The indication for pneumococcal pneumonia is under accelerat.
Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
The average of price targets set by Wall Street analysts indicates a potential upside of 32.3% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ligand (LGND) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences: Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 29, 2024. Goldman Sachs Global Healthcare Conference (Miami). Management will present on June 12, 2024 at 4:00 p.m. ET. Managemen.
There is increasing optimism about Ligand's earnings potential, leading to its upgrade to a Zacks Rank #1 (Strong Buy) and potential for higher movement in the stock.
Royalty aggregators such as Royalty Pharma, Ligand, and XOMA are becoming increasingly popular in the biotech sector. They acquire royalty rights to pharmaceutical products from biotech companies, offering them immediate cash in exchange. This arrangement enables biotech firms to secure funding for research and development, while the aggregators profit from their investment.
FAQ
- What is the primary business of Ligand Pharmaceuticals Incorporated?
- What is the ticker symbol for Ligand Pharmaceuticals Incorporated?
- Does Ligand Pharmaceuticals Incorporated pay dividends?
- What sector is Ligand Pharmaceuticals Incorporated in?
- What industry is Ligand Pharmaceuticals Incorporated in?
- What country is Ligand Pharmaceuticals Incorporated based in?
- When did Ligand Pharmaceuticals Incorporated go public?
- Is Ligand Pharmaceuticals Incorporated in the S&P 500?
- Is Ligand Pharmaceuticals Incorporated in the NASDAQ 100?
- Is Ligand Pharmaceuticals Incorporated in the Dow Jones?
- When was Ligand Pharmaceuticals Incorporated's last earnings report?
- When does Ligand Pharmaceuticals Incorporated report earnings?
- Should I buy Ligand Pharmaceuticals Incorporated stock now?